Jacob LaStant

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Claire L. Langrish, J. Michael Bradshaw, Michelle Francesco et al. · The Journal of Immunology · 2021 · 108 citations · Full text

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors

Ken A. Brameld, Timothy D. Owens, Erik Verner et al. · Journal of Medicinal Chemistry · 2017 · 95 citations · Full text

Drug Target, Solid Tumors, Pharmacotherapy +20

Suppression of Glomerulonephritis in Lupus‐Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase

Paola Mina‐Osorio, Jacob LaStant, Natalie Keirstead et al. · Arthritis & Rheumatism · 2013 · 82 citations

Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

Michael Basler, Michelle Lindström, Jacob LaStant et al. · EMBO Reports · 2018 · 70 citations · Full text

Molecular Immunology, Autoimmune Disease, Autoantibody Production +11

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Timothy D. Owens, Ken A. Brameld, Erik Verner et al. · Journal of Medicinal Chemistry · 2022 · 65 citations · Full text